Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | EVP Research & Preclinical Dev | December 28, 2020 | March 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date December 28, 2020 · Filed March 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,351 |
Ending reported balance
After 2021-03-02 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2020-12-28 · Exercise / conversion · Acquired 8,000 · Balance 21,500 Row 2 · 2020-12-28 · Sale · Disposed 149 · Balance 21,351 Row 3 · 2021-03-02 · Exercise / conversion · Acquired 5,195 · Balance 26,546 Row 4 · 2021-03-02 · Sale · Disposed 2,295 · Balance 24,251 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2021-03-02 · Sale · Disposed 2,900 · Balance 21,351 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.13 to $63.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2028-04-02 | Direct | 88,069 |
Reported balance
After 2020-12-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-28 · Exercise / conversion · Disposed 8,000 · Balance 88,069 F4: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.00 · Expires 2031-03-01 | Direct | 40,800 |
Reported balance
After 2021-03-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-02 · Grant · Acquired 40,800 · Balance 40,800 F5: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2028-04-02 | Direct | 82,874 |
Reported balance
After 2021-03-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-02 · Exercise / conversion · Disposed 5,195 · Balance 82,874 F4: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.13 to $63.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
F5: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2021 Filed Mar 4, 2021 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,195 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-21-017869 · doc4.xml · derivative · entry 8 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,874 Underlying: Common Stock · 5,195 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (right to buy) · Derivative | 40,800 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017869 · doc4.xml · derivative · entry 7 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,800 Underlying: Common Stock · 40,800 shares Expires 2031-03-01 F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,900 | $63.52 | $184,194.95 |
DisclosureSEC source: 0001209191-21-017869 · doc4.xml · nonDerivative · entry 5 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,351 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.13 to $63.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,295 | $62.46 | $143,351.44 |
DisclosureSEC source: 0001209191-21-017869 · doc4.xml · nonDerivative · entry 4 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,251 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,195 | $0.60 | $3,117.00 |
DisclosureSEC source: 0001209191-21-017869 · doc4.xml · nonDerivative · entry 3 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2020 Filed Mar 4, 2021 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-21-017869 · doc4.xml · derivative · entry 6 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,069 Underlying: Common Stock · 8,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 28, 2020 Filed Mar 4, 2021 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 149 | $58.73 | $8,750.77 |
DisclosureSEC source: 0001209191-21-017869 · doc4.xml · nonDerivative · entry 2 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,351 Read SEC document |
| December 28, 2020 Filed Mar 4, 2021 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 8,000 | $0.60 | $4,800.00 |
DisclosureSEC source: 0001209191-21-017869 · doc4.xml · nonDerivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,503 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · derivative · entry 9 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,386 Underlying: Common Stock · 1,503 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 3/48th of the total shares on January 22, 2019, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,497 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · derivative · entry 8 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,069 Underlying: Common Stock · 30,497 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 7,225 | $38.42 | $277,585.95 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 6 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.19 to $38.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 24,775 | $37.64 | $932,578.07 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 5 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,725 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.18 to $38.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,503 | $2.19 | $3,291.57 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 4 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 30,497 | $0.60 | $18,298.20 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 3 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:52 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,851 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · derivative · entry 7 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,566 Underlying: Common Stock · 5,851 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:52 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,851 | $40.00 | $234,041.76 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 2 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:52 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,851 | $0.60 | $3,510.60 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2020 Filed Oct 13, 2020 21:43 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,649 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-054703 · doc4.xml · derivative · entry 3 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,417 Underlying: Common Stock · 1,649 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 13, 2020 Filed Oct 13, 2020 21:43 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,649 | $40.00 | $65,960.00 |
DisclosureSEC source: 0001209191-20-054703 · doc4.xml · nonDerivative · entry 2 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 13, 2020 Filed Oct 13, 2020 21:43 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,649 | $0.60 | $989.40 |
DisclosureSEC source: 0001209191-20-054703 · doc4.xml · nonDerivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-034096 · doc4.xml · derivative · entry 5 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,889 Underlying: Common Stock · 20,000 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 3/48th of the total shares on January 22, 2019, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,230 | $27.48 | $33,801.51 |
DisclosureSEC source: 0001209191-20-034096 · doc4.xml · nonDerivative · entry 4 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.55 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 7,875 | $26.91 | $211,920.98 |
DisclosureSEC source: 0001209191-20-034096 · doc4.xml · nonDerivative · entry 3 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,730 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.39 to $27.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,895 | $25.82 | $281,314.35 |
DisclosureSEC source: 0001209191-20-034096 · doc4.xml · nonDerivative · entry 2 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,605 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.39 to $26.36 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 20,000 | $2.19 | $43,800.00 |
DisclosureSEC source: 0001209191-20-034096 · doc4.xml · nonDerivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-032149 · doc4.xml · derivative · entry 3 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,066 Underlying: Common Stock · 7,500 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 7,500 | $30.00 | $225,000.00 |
DisclosureSEC source: 0001209191-20-032149 · doc4.xml · nonDerivative · entry 2 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 7,500 | $0.60 | $4,500.00 |
DisclosureSEC source: 0001209191-20-032149 · doc4.xml · nonDerivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2020 Filed Apr 15, 2020 23:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-024546 · doc4.xml · derivative · entry 4 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,566 Underlying: Common Stock · 7,500 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 31, 2020 Filed Apr 15, 2020 23:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 7,500 | $0.60 | $4,500.00 |
DisclosureSEC source: 0001209191-20-024546 · doc4.xml · nonDerivative · entry 2 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2020 Filed May 26, 2020 21:57 UTC Amendment | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-032146 · doc4a.xml · derivative · entry 2 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,566 Underlying: Common Stock · 7,500 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 22:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-20-021317 · doc4.xml · derivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 20, 2019 Filed Apr 15, 2020 23:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-024546 · doc4.xml · derivative · entry 3 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,066 Underlying: Common Stock · 6,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 20, 2019 Filed Apr 15, 2020 23:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 6,000 | $0.60 | $3,600.00 |
DisclosureSEC source: 0001209191-20-024546 · doc4.xml · nonDerivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed May 26, 2020 21:57 UTC Amendment | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-032146 · doc4a.xml · derivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,066 Underlying: Common Stock · 6,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.